RE: Better than expected21 Jul 2020 16:31
Couple of questions i've been asked
Does it matter only 100 patients in trial? Not really as IFN-b has been used for years and is a naturally occurring protein in our bodies not some mad scientist concocted drug. The trial was gold standard double blind placebo, this particular trial had 100 people but it's been used and tested on humans for 15 years
out of interest what would stop another pharma making the same product.?
Plenty of pharmas already use IFN-b, the huge difference is they can only administer it through IV due to the fact that SNG owns the worldwide patent since 2009 of the delivery method of IFN-b virally. What it means is we already know interferons work and already have a benefit but through IV it's a far higher dose, more costly, less effective, more side effects, takes longer to get to the infected area (lungs) less gets there and so on. SNG protected method is no injections 100% delivery direct into lungs immediately.
What about a vaccine? Done this to death A lot of people that have just invested as it's big news may not be aware of how significant this is, a vaccine takes years to develop and are for a particular strain. By the time one has been developed for covid-19 it will have mutated into covid 22 for example and be useless NVM vaccine is a poisonous word and a man made concoction. SNG have the viral treatment (A naturally occuring protein our body produces) for sars mers asthma copd future strains and mutations and they own the patents in UK europe us and Asia. This literally is the holy grail and is just a puff once a day on a nebuliser no hospital no injections absolute worldwide game changer
How far will it go? 150 million shares in issue at mcap of £500M gives us £3.60 per share, however I feel there is no chance of Richard & co dedicating 15 years of their life and have the golden ticket and not getting their just rewards.
My target is £2B buyout £13.50 a share
Sign In
Follow the stocks
